Open AccessSelective interstitial doxorubicin for recurrent glioblastoma
Author(s) -
Matcovschii Valerii,
Lisii Dan,
Gudumac Valentin,
Dorosenco Stanislav
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2546
Subject(s) - medicine , doxorubicin , chemotherapy , glioblastoma , blood–brain barrier , brain tumor , pathology , pharmacology , cancer research , oncology , central nervous system
Poor delimitation from the viable brain, great genetic heterogeneity, lack of tumor vascularisation are factors that preclude intravenous chemotherapy. Interstitial chemotherapy could be a strategy to avoid a blood‐brain barrier and to assure a minimal dose concentration of the chemotherapy agent. Doxorubicin might be devoid of neurotoxic effects and still efficient on remaining far‐infiltrated tumor cells.